Fujifilm Pharma to market Loramyc for Sosei

February 04, 2014 12:00 PM Eastern Standard Time

PARIS – BioAlliance Pharma SA (Paris:BIO), which develops orphan oncology products, announced that its Japanese partner, Sosei Co. Ltd, has entered into a distribution agreement with Fujifilm Pharma Co., Ltd, for commercialization rights in Japan for Loramyc? (miconazole Lauriad?) mucoadhesive tablet.

Sosei, a biopharmaceutical company of Japanese origin that develops and commercializes innovative drugs globally, has signed a distribution agreement with Fujifilm Pharma for the commercialization of Loramyc in Japan, once its marketing authorization is obtained.

In May 2011, BioAlliance Pharma signed a licensing agreement with Sosei to conduct bridging development program and commercialization rights in Japan for Loramyc in the treatment of oropharyngeal candidiasis. Following a phase I clinical trial finalized in July 2012, Sosei had started a phase III open-label study in March 2013 which should be the final step before submission, as required by the Japanese authorities.

 “We believe that the distribution agreement with Fujifilm Pharma, which has expertise in infectious diseases, will help us expand the reach of Loramyc to more oropharyngeal candidiasis patients,” said Shinichi Tamura, CEO of Sosei Group Corporation.

“The development plan of Loramyc in Japan is driven efficiently and in the timelines scheduled by our partner Sosei. Their partnership with Fujifilm Pharma is implementing an optimized framework to start the commercialization of the product in Japan, one of the major markets in Asia”, adds Judith Greciet, CEO of BioAlliance Pharma.